1 – 4 of 4
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
(
- Contribution to journal › Article
-
Mark
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
(
- Contribution to journal › Article
-
Mark
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo.
(
- Contribution to journal › Article
- 2011
-
Mark
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
(
- Contribution to journal › Article